Looking for a tablet alternative to Mounjaro? Here's what's now available in the UK

What's actually different about the way each medicine works?

Mounjaro (tirzepatide) is a dual-action medicine that activates two gut-hormone receptors (GIP and GLP-1) involved in appetite regulation and blood-sugar control. The Wegovy pill activates the GLP-1 receptor only. That single-pathway versus dual-pathway distinction matters clinically, which is one reason the two medicines produce different average weight-loss figures in trials and why a prescriber weighs up your individual profile rather than treating them as interchangeable.

Mounjaro is a once-weekly subcutaneous injection delivered via a pre-filled KwikPen. The Wegovy pill is taken once daily by mouth, first thing in the morning, on an empty stomach, with a small amount of plain water, waiting at least 30 minutes before eating, drinking anything else, or taking other oral medicines. No refrigeration is needed; you can keep it in a handbag or bedside drawer rather than the fridge door, which for some people genuinely changes the day-to-day practicality of treatment.

Both medicines slow gastric emptying and reduce appetite. Both start at a low dose and are titrated gradually by the prescriber to reduce gastrointestinal side effects. The most common side effects for each are GI-led: nausea, loose stools, constipation, indigestion. These are typically most noticeable at the start or after a dose increase, and tend to settle. The NHS medicines page for tirzepatide and the equivalent semaglutide page each list side effects clearly and are worth reading before starting either treatment.

How the trial evidence compares for someone weighing this up

The SURMOUNT-1 trial (thousands of adults with obesity, no diabetes, 72 weeks) reported average body-weight reductions of around 20–21% at the 15mg Mounjaro dose. The OASIS 4 phase-3 trial for the Wegovy pill (307 adults, 64 weeks, without diabetes) reported an average weight loss of approximately 13.6% versus around 2.4% for placebo. Among participants who stayed fully adherent throughout that trial, the figure was closer to 17%.

That gap is real, and it is part of the clinical picture. It does not mean the Wegovy pill is the lesser option for every person, individual response varies, starting weight matters, and tolerability plays a large role in whether someone stays on treatment long enough to see meaningful results. The NICE appraisal of tirzepatide (TA1026) and its separate recommendation for semaglutide give a sense of how the evidence sits in the UK clinical framework, and the head-to-head SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, directly compared tirzepatide against semaglutide 2.4mg injection over 72 weeks, with tirzepatide producing greater average weight loss.

The oral Wegovy pill does not yet have a NICE appraisal, and it is not available on the NHS at the time of writing, a private prescription is the only route. For a broader look at where Mounjaro alternatives sit in the landscape, that page sets out the options clearly.

Who each medicine is licensed for, and what that means in practice

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above if at least one weight-related condition is present (such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea). Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. The Wegovy pill shares a similar licensed population: BMI 30 or above, or 27–29.9 with at least one weight-related condition.

On paper the eligibility overlap is large. In practice, the prescriber's assessment covers far more than the BMI figure: current medicines, medical history, previous weight-loss treatment, and which route is likely to suit this person's circumstances. Oral semaglutide's strict morning routine (empty stomach, plain water, 30-minute wait) means it suits some patients better than others. An injection once a week suits others. Neither is right by default.

Neither medicine is recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. Both are for adults only; the licences do not cover under-18s. A prescriber working through a thorough consultation will cover all of this. If you want to understand the full range of alternatives to Mounjaro, including injectable options, that page maps out the choices alongside the evidence.

Practical questions worth settling before you decide

For many people the injection-versus-tablet question comes down to practicality and confidence. Needles can feel daunting, particularly at the start, though the Mounjaro KwikPen is designed to make self-injection straightforward, and most patients report the anxiety fades quickly. A daily tablet removes that concern entirely, but introduces a stricter daily routine: the 30-minute fasting window each morning is non-negotiable for the medicine to absorb properly. If you are specifically weighing up tablet-based options, our page covering Mounjaro alternatives in tablet form compares the oral choices that are currently available.

Cost is a real factor for a private prescription. The Wegovy pill's pricing at launch, and Mounjaro's pricing at each dose level, are both shown on the Mounjaro cost page, which also explains what a legitimate private price includes (consultation, prescription, delivery and aftercare) and why the cheapest listing is rarely the right benchmark for a prescription medicine. What matters is a genuine supply chain, a proper clinical assessment, and support if something changes. If you are still deciding between treatments, the page on finding an alternative to Mounjaro walks through the key considerations to help you arrive at the right conversation with your prescriber.

A consultation with one of our prescribers (real clinicians, not automated systems) is the right place to settle which direction fits your health picture. There is no pressure and no prescription without a proper review. To check whether you may be eligible and to speak to our clinical team, check your eligibility here.